PipeBio
PipeBio is a Danish cloud-based bioinformatics company (acquired by Benchling in October 2024) that provides antibody, TCR, and peptide sequence analysis tools for academic researchers, biotech companies, and pharmaceutical firms engaged in antibody drug discovery and engineering.
- Company typePrivate
- Founded2020
- HeadquartersHorsens, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What PipeBio does
PipeBio is a Horsens, Denmark-based bioinformatics company founded in 2020 that built a cloud-based platform for analyzing antibody, TCR (T-cell receptor), scFv (single-chain variable fragment), VHH (variable domain of heavy-chain-only antibody), and peptide sequences. The platform ingests next-generation sequencing (NGS) and Sanger data from antibody discovery workflows — including repertoire analysis, hybridoma sequencing, and biopanning — and provides standardized pipelines for annotation, liability detection, clustering, and hit picking, with documented capability to process billions of sequences within days. A central sequence database stores customer antibody repertoires alongside metadata (target specificity, binding affinity) and supports comparison against FDA-approved therapeutic sequences and public databases.
The technology stack includes configurable end-to-end workflows, a REST API for integration with electronic lab notebooks (ELNs) and laboratory information management systems (LIMS), and SSO/SCIM (Single Sign-On / System for Cross-domain Identity Management) support for enterprise identity providers (Okta, Azure AD, Google, Cloudflare, DUO). The proprietary IgLM (Immunoglobulin Language Model) — a generative antibody language model trained on 558M sequences and published in Cell Systems (2023) — enables in-platform sequence generation, infilling, and developability scoring. PipeBio also integrated support for Bruker Cellular Analysis Beacon single-cell sequencing data in April 2024, combining functional assays with sequence analysis.
PipeBio monetizes via tiered annual subscriptions: an Academic tier (up to 5 named users, discounted) and a Commercial tier (starting from 5 named users, custom pricing) that includes enterprise security features. Go-to-market is hybrid: a free trial and self-serve sign-up drive product-led growth (PLG) at the low end, while direct sales and demo requests handle commercial and enterprise accounts. The customer base spans academic institutions (VIB, La Jolla Institute for Immunology, KU Leuven, KTH, WEHI, POSTECH), mid-cap biotech (Bicycle Therapeutics, Inhibrx, Confo Therapeutics, Maxion Therapeutics, Fusion Antibodies), and service providers. The company is ISO 27001 certified (August 2021) and was acquired by Benchling in October 2024 to expand its biologics and antibody drug discovery capabilities, adding 240 new customers in 2024.
PipeBio firmographics
Firmographics- Name
- PipeBio
- Legal name
- PipeBio ApS
- Website
- https://pipebio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- PipeBio is a Danish cloud-based bioinformatics company (acquired by Benchling in October 2024) that provides antibody, TCR, and peptide sequence analysis tools for academic researchers, biotech companies, and pharmaceutical firms engaged in antibody drug discovery and engineering.
- Ownership category
- akta.pro rank
PipeBio industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Computer Systems Design and Related Services (54151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where PipeBio is headquartered
LocationHeadquarters
- HQ city
- Horsens
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
PipeBio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Subscription SaaS: Cloud-based bioinformatics platform offered as subscription service with tiered plans for Academic and Commercial users. Academic plans support up to 5 named users with NGS analysis pricing varying by scale. Commercial plans start from 5 named users and include custom workflows, configurable liability detection, and enterprise features.
- Free Trial / Freemium Entry: Platform offers free trial with quick onboarding to drive product-led growth. Users can get started for free and decide whether to continue with a subscription after the trial period.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Academic Plan - up to 5 named users for academic and non-commercial institutions |
| Subscription | Annual | Commercial Plan - starting from 5 named users for organizations |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
PipeBio product offering
Product offeringCore offering
PipeBio provides a cloud-based bioinformatics platform for BCR, TCR, VHH, scFv, and peptide sequence analysis, supporting antibody discovery workflows from repertoire sequencing through hit picking and antibody engineering. The platform combines standardized analysis pipelines (NGS repertoire analysis, Sanger sequencing, annotation and liability detection, clustering), an integrated sequence database with metadata and public-database comparison, configurable end-to-end workflows, a REST API for ELN/LIMS integration, and the IgLM generative antibody language model for sequence design and developability assessment. Customers include academic research institutions, biotech startups, and large pharmaceutical companies.
Product overview
PipeBio is a cloud-based bioinformatics platform acquired by Benchling in October 2024 to expand biologics and antibody drug discovery capabilities. The platform offers a unified suite for antibody, TCR, and peptide sequence analysis, comprising core applications for antibody discovery (liability identification, biopanning, hit expansion, Sanger analysis, hit picking), antibody engineering tools, a sequence database with public database comparisons, and REST API integration capabilities. The platform also features IgLM, a generative antibody-specific language model for sequence generation and diversification.
Differentiator
Problem solved
Functional benefit
Products and services
- PipeBio Bioinformatics Cloud Cloud-based bioinformatics platform for BCR, TCR, VHH, scFv, and peptide sequence analysis, providing standardized analysis pipelines with interactive tools for annotation, clustering, visualization, hit picking, and antibody engineering. Used by scientists and bioinformaticians from academia, small-to-mid biotechs, and top-10 pharmaceutical companies.
- Antibody Discovery Applications Suite of applications covering the antibody discovery workflow, including liability identification, biopanning analysis, hit expansion, Sanger sequencing analysis, and hit picking for candidate sequence selection. Targeted at wet-lab antibody discovery scientists.
- Antibody Engineering Tools Tools for editing antibody sequences at the nucleotide or protein level, calculating protein properties, optimizing degenerate codons for synthesis, and analyzing sequence hydrophobicity. Used by scientists performing antibody optimization and developability work.
- IgLM (Immunoglobulin Language Model) Generative AI capability for antibody sequence design, infilling, and diversification, conditioned on chain type and species of origin; trained on 558M non-redundant unpaired antibody Fv sequences from human, mouse, rat, rabbit, rhesus, and camel using a decoder-only transformer. Supports evaluation of antibody sequence likelihood and improvement of in silico developability and humanness.
- Sequence Database Central cloud database for storing antibody sequences with associated metadata such as target specificity and binding affinity, with comparison against sequences from experiments and public databases including FDA-approved therapeutic antibodies.
- PipeBio REST API REST API enabling programmatic upload and download of data, integration with ELN, LIMS, and internal tools, and construction of fully automated analysis pipelines. Used by bioinformaticians to embed PipeBio analyses within existing R&D infrastructure.
Quantifiable outcome
- Analyze billions of NGS sequences in a few days
- +1 more outcomes
Companies that use PipeBio
Customer profileNamed customers17 records
Segments4 records
Ideal customer profiles3 records
PipeBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability4 records
Feature8 records
PipeBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BenchlingcorePipeBio was acquired by Benchling in October 2024 to expand Benchling's biologics and antibody drug discovery capabilities. The acquisition combined PipeBio's bioinformatics expertise with Benchling's R&D cloud platform, enabling end-to-end biologics discovery workflows. Benchling's 2024 year-in-review highlighted the acquisition as part of expanding their scientific AI ecosystem.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
PipeBio competitors and assessment
Company assessmentBroad incumbents
- Molecular Devices: Molecular Devices supplies discovery instruments, software, and informatics for biologics research including antibody screening workflows, competing adjacently for budget and workflow ownership in pharma biologics R&D.
- Dotmatics: Dotmatics (now part of Siemens) offers a broad scientific R&D platform spanning ELN, LIMS, and biology informatics including antibody and biologics workflows, competing with PipeBio at the workflow-integration layer for large pharma R&D.
- Benchling: Benchling is the parent company of PipeBio post-acquisition and operates a broader R&D cloud platform that increasingly incorporates native bioinformatics and biologics capabilities, making it both parent and a structural competitor in scientific informatics.
Others
- Biognosys: Biognosys provides proteomics and bioinformatics services and software, including mass-spec-based workflows that are increasingly converging with NGS-based antibody characterization, positioning it as an adjacent informatics peer in deep antibody characterization.
Direct peers
- Genedata: Genedata (Sanger) provides enterprise bioinformatics platforms for biologics, antibody, and high-throughput screening R&D, including repertoire analysis, screening data management, and antibody characterization workflows — the closest direct competitor to PipeBio's antibody discovery platform.
- Geneious (Biomatters): Geneious provides molecular biology and sequence analysis software used by scientists for antibody, TCR, and general sequence workflows; it overlaps with PipeBio's Sanger/NGS sequence analysis capabilities and serves a similar academic and biotech audience.
- DNASTAR: DNASTAR provides sequence analysis and bioinformatics software used in molecular biology and antibody research, with comparable Sanger/NGS analysis tooling aimed at academic and biotech life science customers.
Emerging players
- Schrödinger: Schrödinger operates computational biology and chemistry platforms with growing biologics and antibody modeling capabilities, increasingly intersecting with PipeBio's space of in silico antibody engineering and developability assessment.
- AbCellera Biologics: AbCellera is a tech-enabled antibody discovery company that has built proprietary bioinformatics and AI/ML tooling for repertoire analysis and lead selection, making it a thematic peer in AI-driven antibody discovery even though its primary offering is discovery services.
- Carterra: Carterra provides high-throughput antibody characterization instruments and associated analysis software, overlapping with PipeBio's antibody engineering and biopanning analytics use cases for therapeutic antibody discovery teams.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
PipeBio social profiles
Digital presencePipeBio compliance and trust
Trust signalCompliance1 record
PipeBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
PipeBio leadership team
Management profileNumber of profiles
Profiles2 records
PipeBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PipeBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PipeBio
What does PipeBio do?
PipeBio provides a cloud-based bioinformatics platform for BCR, TCR, VHH, scFv, and peptide sequence analysis, supporting antibody discovery workflows from repertoire sequencing through hit picking and antibody engineering. The platform combines standardized analysis pipelines (NGS repertoire analysis, Sanger sequencing, annotation and liability detection, clustering), an integrated sequence database with metadata and public-database comparison, configurable end-to-end workflows, a REST API for ELN/LIMS integration, and the IgLM generative antibody language model for sequence design and developability assessment. Customers include academic research institutions, biotech startups, and large pharmaceutical companies.
Is PipeBio a public or private company?
PipeBio is a private company. It is classified as corporate owned and is currently acquired.
When was PipeBio founded?
PipeBio was founded in 2020. It employs 1 to 10 people.
Where is PipeBio based?
PipeBio is headquartered in Horsens, Denmark, in the Europe region.
How does PipeBio make money?
Two revenue lines are on record. Subscription SaaS are the primary driver. The others are free Trial / Freemium Entry.
Who are PipeBio's main competitors?
Broad incumbents on record are Molecular Devices, Dotmatics and Benchling. Biognosys is listed as an others. Direct peers are Genedata, Geneious (Biomatters) and DNASTAR. Emerging players are Schrödinger, AbCellera Biologics and Carterra.
Does PipeBio have an API?
Yes. PipeBio offers a REST API that enables users to integrate with their ELN, LIMS, or internal tools. The API supports uploading and downloading data programmatically and building entire automated pipelines. No specific documentation URL, SDK language, or authentication details are provided in the available sources.
What industry is PipeBio in?
PipeBio's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 54151 and its SIC code is 7373.